SOURCE: VigiLanz

June 09, 2008 14:53 ET

Hospitals Use VigiLanz Software for Compliance With Joint Commission National Patient Safety Goal 3E for Anticoagulation Therapy Safety

Software Anticipates and Prevents Adverse Drug Events and Helps With Goal 3E Implementation

MINNEAPOLIS, MN--(Marketwire - June 9, 2008) - Joint Commission 2008 National Patient Safety Goal 3E requires hospitals and clinics to implement systems to "reduce the likelihood of patient harm associated with the use of anticoagulation therapy." VigiLanz Corp., which develops the Dynamic Monitoring System to identify and prevent adverse drug events, can help achieve NPSG 3E compliance and optimize a hospital's overall anticoagulation management strategies.

According to the Joint Commission, "Anticoagulation is a high-risk treatment, which commonly leads to adverse drug events due to the complexity of dosing these medications, monitoring their effects, and ensuring patient compliance with outpatient therapy. The use of standardized practices that include patient involvement can reduce the risk of adverse drug events associated with the use of heparin (unfractionated), low molecular weight heparin (LMWH), warfarin, and other anticoagulants."

The Joint Commission requires health care providers to have in place by July 1, 2008, a plan regarding "the resources, assigned responsibilities and time line for full implementation" of 3E compliance. By Oct. 1, 2008, providers are expected to have at least one clinical unit undertaking a pilot test. By January 1, 2009, the process for reducing likelihood of harm from anticoagulation therapy must be fully implemented.

"Without a comprehensive, easy to use system in place to guide and monitor adherence to these new safety standards, hospitals and clinics will likely struggle to comply with these important standardized practices," said Dr. David Goldsteen, CEO of VigiLanz. "Our software is a complete medication safety system that helps health care providers identify, monitor and prevent adverse drug events and adhere to clinical best practices."

At the upcoming Summer Meeting and Exhibition of the American Society of Health-System Pharmacists, the first of several sessions in the "Hot Topics" series is a discussion of the Joint Commission's 2008 National Patient Safety Goals and, specifically, these anticoagulation therapy management requirements. Representatives from VigiLanz will be attending the ASHP conference and demonstrating the company's software at booth 840 on the exhibition floor.

About VigiLanz

VigiLanz Corporation was founded in 2001 by two medical doctors seeking to empower pharmacists, physicians and nurses with tools to proactively monitor their patients to identify and prevent adverse drug events, and to support adherence to clinical best practices. Prevention remains one of the core benefits of the VigiLanz Dynamic Monitoring System, an automated 24/7 patient monitoring system that enables real-time patient safety monitoring and can reduce preventable ADEs and other adverse events by 50 percent or more. The Dynamic Monitoring System is the first comprehensive, rules-based software that merges the patient's clinical data with the hospital's own clinical best-practice guidelines to empower clinicians to anticipate, identify and prevent adverse events and optimize clinical outcomes. (www.vigilanzcorp.com)

Contact Information